Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Ranging Booster Study of VLPCOV-01 After mRNA COVID-19 Vaccination
jRCT2051220087Phase 2Completed
- Sponsor
- VLP Therapeutics Japan
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VLPCOV-04 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by VLP Therapeutics Japan. Primary endpoints: GMT of neutralizing antibody titers against live virus and pseudovirus, Seroresponse rate (SRR) of neutralizing antibody titers and 4 more. Started Sep 2022; status: completed.
02
Drugs
VLPCOV-04
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051220087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220087.